Subscribe Subscribe   Find us on Twitter Follow POL on Twitter  



No, Ours Is Better

General Electric must reimburse a competitor $8.3 million for ads it has already run and $3 million for future ads after a GE subsidiary claimed that its x-ray contrast agent was better than the competitor's--a misconstruction of a clinical study, said the court. But which is actually better? The experts were divided, and "the weight of clinical evidence," said the court, did not point either way.

Related Entries:



Isaac Gorodetski
Project Manager,
Center for Legal Policy at the
Manhattan Institute

Katherine Lazarski
Press Officer,
Manhattan Institute


Published by the Manhattan Institute

The Manhattan Insitute's Center for Legal Policy.